{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:24:16Z","timestamp":1782786256946,"version":"3.54.5"},"reference-count":93,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.det.2007.01.002","type":"journal-article","created":{"date-parts":[[2007,4,11]],"date-time":"2007-04-11T07:13:35Z","timestamp":1176275615000},"page":"165-183","source":"Crossref","is-referenced-by-count":71,"title":["Advances in Topical and Systemic Antifungals"],"prefix":"10.1016","volume":"25","author":[{"given":"Alexandra Y.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boni E.","family":"Elewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.det.2007.01.002_bib1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S1369-5274(98)80087-8","article-title":"Antifungals: mechanism of action and resistance, established and novel drugs","volume":"1","author":"Georgopapadakou","year":"1998","journal-title":"Curr Opin Microbiol"},{"issue":"2911","key":"10.1016\/j.det.2007.01.002_bib2","first-page":"423","article-title":"Two antifungal agents produced by a soil actinomycete","volume":"112","author":"Hazen","year":"1950","journal-title":"Science"},{"key":"10.1016\/j.det.2007.01.002_bib3","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1749-6632.1960.tb20148.x","article-title":"Nystatin","volume":"89","author":"Hazen","year":"1960","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.det.2007.01.002_bib4","series-title":"The pharmacological basis of therapeutics","first-page":"1165","article-title":"Antimicrobial agents: antifungal agents","author":"Bennett","year":"1993"},{"issue":"6","key":"10.1016\/j.det.2007.01.002_bib5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1399-302X.2005.00236.x","article-title":"In vitro susceptibility of oral Candida to seven antifungal agents","volume":"20","author":"Kuriyama","year":"2005","journal-title":"Oral Microbiol Immunol"},{"issue":"2","key":"10.1016\/j.det.2007.01.002_bib6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/archderm.102.2.216","article-title":"Allergic contact dermatitis from nystatin","volume":"102","author":"Wasilewski","year":"1970","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.det.2007.01.002_bib7","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/archderm.127.5.741","article-title":"Stevens-Johnson syndrome associated with nystatin treatment","volume":"127","author":"Garty","year":"1991","journal-title":"Arch Dermatol"},{"issue":"7","key":"10.1016\/j.det.2007.01.002_bib8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00520-004-0634-1","article-title":"Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy","volume":"12","author":"Epstein","year":"2004","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.det.2007.01.002_bib9","first-page":"579","article-title":"Amphotericins A and B, antifungal anitbiotics produced by streptomycete I in vitro studies","volume":"3","author":"Gold","year":"1955","journal-title":"Antibiotics Ann"},{"issue":"1","key":"10.1016\/j.det.2007.01.002_bib10","first-page":"67","article-title":"Development of liposomal polyene antibiotics: an historical perspective","volume":"6","author":"Ng","year":"2003","journal-title":"J Pharm Pharm Sci"},{"issue":"Suppl 1","key":"10.1016\/j.det.2007.01.002_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/49.suppl_1.7","article-title":"Amphotericin B: spectrum and resistance","volume":"49","author":"Ellis","year":"2002","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.det.2007.01.002_bib12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s10096-005-0080-0","article-title":"Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis","volume":"25","author":"Girois","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.det.2007.01.002_bib13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijantimicag.2006.03.013","article-title":"What is the current and future status of conventional amphotericin B?","volume":"27","author":"Kleinberg","year":"2006","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1016\/j.det.2007.01.002_bib14","first-page":"1260","article-title":"Synthesis and properties of clotrimazole and other antimycotic 1-triphenylmethylimidazoles","volume":"22","author":"Buchel","year":"1972","journal-title":"Arzneimittelforschung"},{"issue":"12","key":"10.1016\/j.det.2007.01.002_bib15","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1136\/jcp.25.12.1089","article-title":"Laboratory assessment of the antimycotic drug clotrimazole","volume":"25","author":"Holt","year":"1972","journal-title":"J Clin Pathol"},{"issue":"3","key":"10.1016\/j.det.2007.01.002_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1365-2133.1973.tb02978.x","article-title":"Comparison of clotrimazole cream, Whitfield's ointment and nystatin ointment for the topical treatment of ringworm infections, pityriasis versicolor, erythrasma and candidiasis","volume":"89","author":"Clayton","year":"1973","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2007.01.002_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1440-0960.1983.tb00245.x","article-title":"Treatment of cutaneous candidiasis: a double blind, parallel comparison of sulconazole nitrate 1% cream and clotrimazole 1% cream","volume":"24","author":"Rajan","year":"1983","journal-title":"Australas J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2007.01.002_bib18","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1021\/jm00305a014","article-title":"The preparation and antimycotic properties of derivatives of 1-phenethylimidazole","volume":"12","author":"Godefroi","year":"1969","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.det.2007.01.002_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003495-197816030-00001","article-title":"Econazole: a review of its antifungal activity and therapeutic efficacy","volume":"16","author":"Heel","year":"1978","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.det.2007.01.002_bib20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0536.1992.tb00260.x","article-title":"Allergic contact dermatitis due to sulconazole","volume":"26","author":"Bigardi","year":"1992","journal-title":"Contact Dermatitis"},{"issue":"6","key":"10.1016\/j.det.2007.01.002_bib21","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2165\/00003495-199039060-00006","article-title":"Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses","volume":"39","author":"Grant","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.det.2007.01.002_bib22","unstructured":"Fluconazole [package insert]. New York: Pfizer Roerig; 1997."},{"issue":"7\u20138","key":"10.1016\/j.det.2007.01.002_bib23","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1345\/aph.1G741","article-title":"Long QTc interval and torsade de pointes caused by fluconazole","volume":"40","author":"Pham","year":"2006","journal-title":"Ann Pharmacother"},{"issue":"8759","key":"10.1016\/j.det.2007.01.002_bib24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0140-6736(91)90112-3","article-title":"Stevens-Johnson syndrome after fluconazole","volume":"338","author":"Gussenhoven","year":"1991","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.det.2007.01.002_bib25","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/pds.1073","article-title":"Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions","volume":"14","author":"Yu","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.det.2007.01.002_bib26","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0190-9622(94)70112-1","article-title":"Antifungal agents: an overview. Part II","volume":"30","author":"Gupta","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.det.2007.01.002_bib27","unstructured":"Itraconazole [package insert]. Titusville (NJ): Janssen; 1996."},{"issue":"3 Pt 1","key":"10.1016\/j.det.2007.01.002_bib28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(97)80215-0","article-title":"Onychomycosis in children: prevalence and treatment strategies","volume":"36","author":"Gupta","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2007.01.002_bib29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1046\/j.1365-2133.1997.18141912.x","article-title":"Itraconazole pulse therapy is effective in the treatment of tinea capitis in children: an open multicentre study","volume":"137","author":"Gupta","year":"1997","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2007.01.002_bib30","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0190-9622(97)70074-4","article-title":"Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview","volume":"37","author":"Doncker","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2007.01.002_bib31","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1021\/jm00194a023","article-title":"Antimycotic imidazoles. Part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent","volume":"22","author":"Heeres","year":"1979","journal-title":"J Med Chem"},{"issue":"3 Suppl","key":"10.1016\/j.det.2007.01.002_bib32","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/1097-0142(19930201)71:3+<1068::AID-CNCR2820711427>3.0.CO;2-5","article-title":"Ketoconazole and liarozole in the treatment of advanced prostatic cancer","volume":"71","author":"Mahler","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.det.2007.01.002_bib33","unstructured":"Nizoral tablets [package insert]. Titusville (NJ): Janssen Pharmaceutica; 2001."},{"issue":"1","key":"10.1016\/j.det.2007.01.002_bib34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/jac\/6.1.97","article-title":"The activity in vitro and in vivo of a new imidazole antifungal, ketoconazole","volume":"6","author":"Odds","year":"1980","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.det.2007.01.002_bib35","first-page":"181","article-title":"Ketoconazole 2 percent cream in the treatment of tinea pedis, tinea cruris, and tinea corporis","volume":"55","author":"Lester","year":"1995","journal-title":"Cutis"},{"issue":"5 Pt 1","key":"10.1016\/j.det.2007.01.002_bib36","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0190-9622(08)81495-8","article-title":"Antifungal agents: an overview. Part I","volume":"30","author":"Gupta","year":"1994","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2007.01.002_bib37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1586\/14787210.4.2.171","article-title":"Miconazole: a historical perspective","volume":"4","author":"Fothergill","year":"2006","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"10.1016\/j.det.2007.01.002_bib38","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1159\/000220875","article-title":"Miconazole, a broad-spectrum antimycotic agent with antibacterial activity","volume":"17","author":"Van Cutsem","year":"1972","journal-title":"Chemotherapy"},{"issue":"2","key":"10.1016\/j.det.2007.01.002_bib39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1600-0536.1995.tb00504.x","article-title":"Contact allergy to imidazoles used as antimycotic agents","volume":"33","author":"Dooms-Goossens","year":"1995","journal-title":"Contact Dermatitis"},{"issue":"4","key":"10.1016\/j.det.2007.01.002_bib40","first-page":"305","article-title":"Comparison of an antifungal agent used alone with an antifungal used with a topical steroid in inflammatory tinea pedis","volume":"58","author":"Elewski","year":"1996","journal-title":"Cutis"},{"issue":"1","key":"10.1016\/j.det.2007.01.002_bib41","first-page":"126","article-title":"Oxiconazole nitrate: pharmacology, efficacy, and safety of a new imidazole antifungal agent","volume":"13","author":"Jegasothy","year":"1991","journal-title":"Clin Ther"},{"key":"10.1016\/j.det.2007.01.002_bib42","unstructured":"Vfend [package insert]. New York: Pfizer Roerig; 2003."},{"issue":"4","key":"10.1016\/j.det.2007.01.002_bib43","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1586\/14787210.2.4.485","article-title":"Voriconazole: therapeutic review of a new azole antifungal","volume":"2","author":"Herbrecht","year":"2004","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"12","key":"10.1016\/j.det.2007.01.002_bib44","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1128\/AAC.49.12.5157-5159.2005","article-title":"Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp and Fusarium solani","volume":"49","author":"Heyn","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"5 Suppl 1","key":"10.1016\/j.det.2007.01.002_bib45","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.jaad.2004.07.034","article-title":"Photoaging and phototoxicity from long-term voriconazole treatment in a 15-year-old girl","volume":"52","author":"Racette","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"10.1016\/j.det.2007.01.002_bib46","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.2165\/00003495-200464180-00001","article-title":"Newer systemic antifungal agents: pharmacokinetics, safety and efficacy","volume":"64","author":"Boucher","year":"2004","journal-title":"Drugs"},{"issue":"7\u20138","key":"10.1016\/j.det.2007.01.002_bib47","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1439-0507.1997.tb00227.x","article-title":"The hydroxypyridones: a class of antimycotics of its own","volume":"40","author":"Korting","year":"1997","journal-title":"Mycoses"},{"issue":"4","key":"10.1016\/j.det.2007.01.002_bib48","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0738-081X(91)90075-V","article-title":"Ciclopirox olamine: a hydroxypyridone antifungal agent","volume":"9","author":"Abrams","year":"1991","journal-title":"Clin Dermatol"},{"issue":"3","key":"10.1016\/j.det.2007.01.002_bib49","first-page":"290","article-title":"Ciclopirox olamine lotion 1%: bioequivalence to ciclopirox olamine cream 1% and clinical efficacy in tinea pedis","volume":"11","author":"Aly","year":"1989","journal-title":"Clin Ther"},{"key":"10.1016\/j.det.2007.01.002_bib50","series-title":"Physician's desk reference","first-page":"1327","article-title":"Ciclopirox olamine","year":"1999"},{"issue":"4","key":"10.1016\/j.det.2007.01.002_bib51","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/030006058601400408","article-title":"Multicentre double-blind clinical trials of ciclopirox olamine cream 1% in the treatment of tinea corporis and tinea cruris","volume":"14","author":"Bogaert","year":"1986","journal-title":"J Int Med Res"},{"issue":"4","key":"10.1016\/j.det.2007.01.002_bib52","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2165\/00003495-198529040-00002","article-title":"Ciclopirox olamine 1% cream: a preliminary review of its antimicrobial activity and therapeutic use","volume":"29","author":"Jue","year":"1985","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.det.2007.01.002_bib53","first-page":"232","article-title":"Studies in the biochemistry of micro-organisms: Griseofulvin, C(17)H(17)O(6)C1, a metabolic product of Peincillium griseofulvum Dierckx","volume":"49","author":"Oxford","year":"2006","journal-title":"Mycoses"},{"issue":"6","key":"10.1016\/j.det.2007.01.002_bib54","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0022-3476(88)80232-4","article-title":"Treating tinea capitis: should ketoconazole replace griseofulvin?","volume":"112","author":"Tanz","year":"1988","journal-title":"J\u00a0Pediatr"},{"issue":"1","key":"10.1016\/j.det.2007.01.002_bib55","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1525-1470.1997.tb00427.x","article-title":"Lack of efficacy of 6-week treatment with oral terbinafine for tinea capitis due to Microsporum canis in children","volume":"14","author":"Dragos","year":"1997","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"10.1016\/j.det.2007.01.002_bib56","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1525-1470.2000.01784.x","article-title":"Oral griseofulvin remains the treatment of choice for tinea capitis in children","volume":"17","author":"Bennett","year":"2000","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"10.1016\/j.det.2007.01.002_bib57","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0190-9622(08)80010-2","article-title":"Interaction of griseofulvin and oral contraceptives","volume":"22","author":"Cote","year":"1990","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2007.01.002_bib58","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1042\/bj2300765","article-title":"Inhibition of squalene epoxidase by allylamine antimycotic compounds: a comparative study of the fungal and mammalian enzymes","volume":"230","author":"Ryder","year":"1985","journal-title":"Biochem J"},{"issue":"3","key":"10.1016\/j.det.2007.01.002_bib59","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1042\/bst0190774","article-title":"Squalene epoxidase as a target for the allylamines","volume":"19","author":"Ryder","year":"1991","journal-title":"Biochem Soc Trans"},{"issue":"4","key":"10.1016\/j.det.2007.01.002_bib60","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2165\/00003495-199142040-00008","article-title":"Naftifine: a review of its antimicrobial activity and therapeutic use in superficial dermatomycoses","volume":"42","author":"Monk","year":"1991","journal-title":"Drugs"},{"issue":"1 Pt 1","key":"10.1016\/j.det.2007.01.002_bib61","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0190-9622(88)70008-0","article-title":"Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis","volume":"18","author":"Millikan","year":"1988","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.det.2007.01.002_bib62","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000246183","article-title":"Oral terbinafine (Lamisil) in the treatment of fungal infections of the skin and nails","volume":"194","author":"Roberts","year":"1997","journal-title":"Dermatology"},{"issue":"Suppl 39","key":"10.1016\/j.det.2007.01.002_bib63","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2133.1992.tb00002.x","article-title":"Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers","volume":"126","author":"Kovarik","year":"1992","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2007.01.002_bib64","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2230.1994.tb01138.x","article-title":"Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days","volume":"19","author":"Faergemann","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"9","key":"10.1016\/j.det.2007.01.002_bib65","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1128\/AAC.31.9.1365","article-title":"Antifungal activity of the allylamine derivative terbinafine in vitro","volume":"31","author":"Petranyi","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.det.2007.01.002_bib66","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/00362178585380201","article-title":"In vitro studies with SF 86-327, a new orally active allylamine derivative","volume":"23","author":"Shadomy","year":"1985","journal-title":"Sabouraudia"},{"issue":"2","key":"10.1016\/j.det.2007.01.002_bib67","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1365-2230.1989.tb00905.x","article-title":"Clinical efficacy of terbinafine in 629 Japanese patients with dermatomycosis","volume":"14","author":"Kagawa","year":"1989","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"10.1016\/j.det.2007.01.002_bib68","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0190-9622(08)81787-2","article-title":"Topical terbinafine and clotrimazole in interdigital tinea pedis: a multicenter comparison of cure and relapse rates with 1- and 4-week treatment regimens","volume":"28","author":"Bergstresser","year":"1993","journal-title":"J Am Acad Dermatol"},{"issue":"6905","key":"10.1016\/j.det.2007.01.002_bib69","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/bmj.307.6905.645","article-title":"Comparison of terbinafine and clotrimazole in treating tinea pedis","volume":"307","author":"Evans","year":"1993","journal-title":"BMJ"},{"issue":"31","key":"10.1016\/j.det.2007.01.002_bib70","first-page":"1605","article-title":"[Terbinafine versus miconazole in patients with tinea pedis]","volume":"140","author":"Vermeer","year":"1996","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"4 Pt 2","key":"10.1016\/j.det.2007.01.002_bib71","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/0190-9622(90)70289-T","article-title":"Treatment of chronic tinea pedis (athlete's foot type) with topical terbinafine","volume":"23","author":"Savin","year":"1990","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2007.01.002_bib72","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1346-8138.1996.tb04009.x","article-title":"Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach","volume":"23","author":"Alpsoy","year":"1996","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2007.01.002_bib73","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1046\/j.1365-4362.1998.00402.x","article-title":"Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus","volume":"37","author":"Tausch","year":"1998","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2007.01.002_bib74","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2230.1989.tb00908.x","article-title":"Clinical efficacy and tolerability of terbinafine (Lamisil): a new topical and systemic fungicidal drug for treatment of dermatomycoses","volume":"14","author":"Villars","year":"1989","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.det.2007.01.002_bib75","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00128071-200304010-00005","article-title":"Terbinafine: a review of its use in onychomycosis in adults","volume":"4","author":"Darkes","year":"2003","journal-title":"Am J Clin Dermatol"},{"issue":"2 Pt 1","key":"10.1016\/j.det.2007.01.002_bib76","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S0190-9622(97)70318-9","article-title":"Butenafine 1% cream in the treatment of tinea cruris: a multicenter, vehicle-controlled, double-blind trial","volume":"36","author":"Lesher","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2007.01.002_bib77","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1248\/yakushi1947.111.2_126","article-title":"Synthesis and antifungal activity of butenafine hydrochloride (KP-363), a new benzylamine antifungal agent","volume":"111","author":"Maeda","year":"1991","journal-title":"Yakugaku Zasshi"},{"issue":"3","key":"10.1016\/j.det.2007.01.002_bib78","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1517\/14656566.1.3.467","article-title":"Butenafine hydrochloride: for the treatment of interdigital tinea pedis","volume":"1","author":"Syed","year":"2000","journal-title":"Expert Opin Pharmacother"},{"issue":"2 Pt 1","key":"10.1016\/j.det.2007.01.002_bib79","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S0190-9622(97)70317-7","article-title":"One-week therapy with twice-daily butenafine 1% cream versus vehicle in the treatment of tinea pedis: a multicenter, double-blind trial","volume":"36","author":"Savin","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2007.01.002_bib80","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0966-842X(03)00117-3","article-title":"Antifungal agents: mechanisms of action","volume":"11","author":"Odds","year":"2003","journal-title":"Trends Microbiol"},{"issue":"3","key":"10.1016\/j.det.2007.01.002_bib81","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1128\/AAC.46.3.739-745.2002","article-title":"Single- and multiple-dose pharmacokinetics of caspofungin in healthy men","volume":"46","author":"Stone","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.det.2007.01.002_bib82","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1128\/AAC.41.9.1937","article-title":"Treatment of murine Candida krusei or Candida glabrata infection with L-743,872","volume":"41","author":"Graybill","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.det.2007.01.002_bib83","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1128\/AAC.41.8.1775","article-title":"Treatment of murine disseminated candidiasis with L-743,872","volume":"41","author":"Graybill","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"25","key":"10.1016\/j.det.2007.01.002_bib84","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.det.2007.01.002_bib85","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.det.2007.01.002_bib86","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy","volume":"39","author":"Maertens","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.det.2007.01.002_bib87","unstructured":"MSD Sharp & Dohme Ltd. Caspofungin MSD: summary of product characteristics. Available at: http:\/\/www.eudra.org, 2004."},{"issue":"4","key":"10.1016\/j.det.2007.01.002_bib88","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1439-0507.2005.01131.x","article-title":"Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin","volume":"48","author":"Maschmeyer","year":"2005","journal-title":"Mycoses"},{"key":"10.1016\/j.det.2007.01.002_bib89","unstructured":"Hiemenz J, Simpson D, Devine S, et\u00a0al. Maximum tolerated dose and pharmacokinetics of FK463 in combination with fluconazole for the prophylaxis of fungal infections in adult bone marrow or peripheral stem cell transplant patients. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy [abstract 1648]. San Francisco (CA), September 26\u201329, 1999."},{"key":"10.1016\/j.det.2007.01.002_bib90","unstructured":"Mukai T, Nakahara K, Takaya T, et\u00a0al. Pharmacokinetics of FK463, a novel echinocandin analogue, in elderly and nonelderly subjects. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, December 16\u201319, 2001."},{"key":"10.1016\/j.det.2007.01.002_bib91","unstructured":"Ostrosky-Zeichner L, Anaissie E, Kontoyiannia D, et\u00a0al. Micafungin (MCFG), an echinocandin antifungal agent for the treatment of new and refractory candidemia [abstract P-35]. Presented at the 13th Annual Focus on Fungal Infections Meeting. Maui (HI), Mar 19\u201321, 2003."},{"key":"10.1016\/j.det.2007.01.002_bib92","unstructured":"Kohno S, Yamaguchi H. A multicenter, open-label clinical study of FK463 in patients with deep mycosis in Japan [abstract]. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Dec 16\u201319, 2001."},{"issue":"Pt 2","key":"10.1016\/j.det.2007.01.002_bib93","first-page":"361","article-title":"Assessment of maximum tolerated dose and pharmacokinetics of FK463 in\u00a0neutropenic patients after haematopoietic stem cell transplantation","volume":"98","author":"Powles","year":"2001","journal-title":"Blood"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863507000034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863507000034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T03:23:16Z","timestamp":1556335396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863507000034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0733863507000034"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2007.01.002","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}